BAP1癌症综合征的基因型与表型特征:8个新家系报告及文献病例综述
该研究描述了8个新发现的家系中10例BAP1胚系突变携带者,并结合文献综述共纳入215例患者,分析基因型与表型关联。结果显示MBAITs在皮肤科门诊患者中常见,BAP1突变携带者中最常见的恶性肿瘤为葡萄膜黑色素瘤(28%)、间皮瘤(22%)、皮肤黑色素瘤(18%)和肾细胞癌(9%)。皮肤科医生可通过个人及家族史和全身皮肤检查识别BAP1癌症综合征高危患者。
要点
- BAP1胚系突变携带者应关注MBAITs,其常早于其他BAP1相关肿瘤出现。
- BAP1突变携带者最常见恶性肿瘤为葡萄膜黑色素瘤、间皮瘤、皮肤黑色素瘤和肾细胞癌。
- 皮肤科医生通过全身皮肤检查识别MBAITs,可帮助筛查BAP1癌症综合征高危患者。
核心结论
- BAP1基因编码区和非编码区的胚系突变均可损害蛋白功能,增加多种相关恶性肿瘤风险。
研究设计与样本
- 研究纳入皮肤科门诊6个月内发现的8个家系共10例突变携带者,并通过PubMed文献综述纳入205例患者,共215例。
- 突变通过唾液或血液样本下一代测序鉴定,并对1例内含子变异患者培养的成纤维细胞提取RNA以确定突变对编码序列的影响。
主要发现
- 215例患者中108例女性、91例男性、16例性别未指明,中位年龄46.5岁(范围10.0-79.0岁)。
- 皮肤科门诊发现的10例患者中9例临床检查发现MBAITs。
- BAP1突变携带者中最常见的恶性肿瘤为葡萄膜黑色素瘤(60例,28%)、间皮瘤(48例,22%)、皮肤黑色素瘤(38例,18%)和肾细胞癌(20例,9%)。
- 共报告71种BAP1独特突变。
临床怎么用
- 皮肤科医生应通过个人及家族史和全身皮肤检查寻找MBAITs,以识别BAP1癌症综合征高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with germline mutations in BAP1 may develop several flesh-colored melanocytic BAP1-mutated atypical intradermal tumors (MBAITs). These tumors generally develop earlier than other BAP1-associated tumors, highlighting an important role for dermatologists in identifying and screening patients with a history suggestive of a germline mutation. OBJECTIVE: To describe 8 new families with germline mutations in BAP1 and provide a comprehensive review of reported cases. DESIGN, SETTINGS AND PARTICIPANTS: Patients were identified in an outpatient dermatology clinical setting over a 6-month period (10 mutation carriers from 8 families) and through a literature review using PubMed (205 patients). EXPOSURES: Mutations were identified through next-generation sequencing of saliva or blood samples, and RNA was extracted from fibroblasts cultured from a patient with an intronic variant to determine the impact of the mutation on the coding sequence. MAIN OUTCOMES AND MEASURES: All 215 patients were assessed for personal and/or family history and genotype. These findings were compiled and assessed for any association between genotype and phenotype. RESULTS: Overall, this study included 215 patients (108 women, 91 men, and 16 gender unspecified; median [range] age, 46.5 [10.0-79.0] years). Nine of the 10 patients who were identified in the outpatient dermatology setting were found to have MBAITs on clinical examination. Forty of 53 patients (75%) identified in the literature review who underwent total-body skin examinations (TBSE) were found to have MBAITs, suggesting a high penetrance in patients who have undergone TBSE. The most prevalent malignancies among BAP1 mutation carriers were uveal melanoma (n = 60 [28%]), mesothelioma (n = 48 [22%]), cutaneous melanoma (n = 38 [18%]), and renal cell carcinoma (n = 20 [9%]). A total of 71 unique mutations in BAP1 have been reported. CONCLUSIONS AND RELEVANCE: Our results indicate that germline mutations in both coding and noncoding regions throughout the BAP1 gene can impair protein function, leading to an increased risk for several associated malignancies. Four of the 8 probands we present had no history of BAP1-associated malignancies and were assessed for germline mutations when found to have MBAITs on dermatologic examination. Dermatologists can identify patients with a high likelihood of the BAP1 cancer syndrome through personal and family history and TBSE for the presence of possible MBAITs.
引用
- Haugh AM, Njauw CN, Bubley JA, et al. Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature. JAMA Dermatol. 2017. PMID: 28793149. doi:10.1001/jamadermatol.2017.2330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。